|
Molecular properties generated using the CDK |
Classification ![]() |
|
Compound class | Synthetic organic |
Approved drug? | Yes (FDA (2019)) |
International Nonproprietary Names ![]() |
|
INN number | INN |
10209 | upadacitinib |
Synonyms ![]() |
ABT-494 | Rinvoq® |
Comments |
Upadacitinib (ABT-494) is a novel second generation orally active Janus kinase inhibitor with high JAK1 selectivity [5,10]. The chemical structure is claimed as compound 1 in Abbvie's patent WO2015061665 [10]. It was developed for potential clinical efficacy in multiple autoimmune diseases. Its first approval was for the treatment of rheumatoid arthritis [2]. |
Database Links ![]() |
|
GtoPdb PubChem SID | 315661321 |
PubChem CID | 58557659 |
Search Google for chemical match using the InChIKey | WYQFJHHDOKWSHR-MNOVXSKESA-N |
Search Google for chemicals with the same backbone | WYQFJHHDOKWSHR |
Search PubMed clinical trials | upadacitinib |
Search PubMed titles | upadacitinib |
Search PubMed titles/abstracts | upadacitinib |
Search UniChem for chemical match using the InChIKey | WYQFJHHDOKWSHR-MNOVXSKESA-N |
Search UniChem for chemicals with the same backbone | WYQFJHHDOKWSHR |